{"id":"NCT00666328","sponsor":"The Medicines Company","briefTitle":"Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE)","officialTitle":"The Evaluation of Patients With Acute Hypertension and Intracerebral Hemorrhage With Intravenous Clevidipine Treatment (ACCELERATE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-06","primaryCompletion":"2010-04","completion":"2010-04","firstPosted":"2008-04-24","resultsPosted":"2013-04-08","lastUpdate":"2014-08-29"},"enrollment":37,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hypertension","Hemorrhage"],"interventions":[{"type":"DRUG","name":"clevidipine","otherNames":["clevidipine injectable emulsion","clevidipine emulsion","Cleviprex"]}],"arms":[{"label":"clevidipine","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to determine the efficacy and safety of clevidipine for treating acute hypertension (high blood pressure, defined as systolic blood pressure \\>160 mmHg) in patients with intracerebral hemorrhage (i.e., bleeding in the brain; stroke).","primaryOutcome":{"measure":"Median Time to Achieve Target SBP Range (≤160 mmHg to ≥140 mmHg) Within 30 Minutes of Initiation of Clevidipine","timeFrame":"Within 30 minutes of study drug initiation","effectByArm":[{"arm":"Clevidipine","deltaMin":5.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":15},"locations":{"siteCount":17,"countries":["United States","Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":35},"commonTop":["Pyrexia","Headache","Hyposphataemia","Agitation","Hypotension"]}}